Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program

18 Jun 2021

Abstract excerpt

Abstract Purpose: Lineage plasticity in prostate cancer—most commonly exemplified by loss of androgen receptor (AR) signaling and a switch from a luminal to alternate differentiation program—is now recognized as a treatment resistance mechanism. Lineage plasticity is a spectrum, but neuroendocrine prostate cancer (NEPC) is the most virulent example. Currently, there are limited treatments for NEPC. Moreover, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to Prostate Cancer Treatment and Research
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34145028
DOI: 10.1158/1078-0432.ccr-20-4968

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity ProgramPMID 34145028Read ↗

The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage PlasticitySemantic proximity Read ↗

Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitorsSemantic proximity Read ↗

Cellular plasticity and the neuroendocrine phenotype in prostate cancer.Semantic proximity Read ↗

N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancerSemantic proximity Read ↗

Therapy considerations in neuroendocrine prostate cancer: what next?Semantic proximity Read ↗

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.Semantic proximity Read ↗

Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancerSemantic proximity Read ↗

The Role of Lineage Plasticity in Prostate Cancer Therapy ResistanceSemantic proximity Read ↗

PROX1 is an early driver of lineage plasticity in prostate cancerSemantic proximity Read ↗

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancerSemantic proximity Read ↗

Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolutionSemantic proximity Read ↗

Targeting Key Players of Neuroendocrine Differentiation in Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.